Investors

Company profile

PDC line Pharma

Spin-off of French Blood Bank (EFS, Etablissement Français du Sang)

SAS founded in April 2014 in Grenoble, France

SA founded in June 2016 in Angleur (Liège, Belgium)

Funding

The company has raised 7,6 M€ in equity on the top of 9,3 M€ of non-dilutive money and is looking to close a new financing round in 2019 to finance a phase 1b / 2 clinical proof of concept study in lung cancer. PDC*line Pharma won numerous awards, including the first prize of the French start-up competition “Tremplin Entreprises” in the biotech category in 2015, and the first prize of the MATWIN oncology projects competition in the start-up category awarded by international leaders from the pharmaceutical industry and academic research.

Based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells (PDC*line)

Target: clinical Proof of Concept by 2021

Partners

R & D

EFS
(Etablissement Français du Sang – French Blood Bank) transferred the PDC*vac technology to PDC*line Pharma, and provides us with privileged access to its research and GMP-compliant manufacturing infrastructures.

Support

Public Service of Wallonia (BELGIUM) – DGO6 Research and Innovation is a Departement of the wallonian Administration that promote wallonian industrial companies to finance their research and innovation programs with a series of financial grants and loans.

bpifrance financements
The French public investment bank for entrepreneurs.